Cargando…

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. The constitutive expression of HIF-1α in MM suggests that inhibition of HIF-1α-mediated transcription represents an interesting target in MM. METHODS: As p300 is a crucial co-activator of hypoxia-inducible transcription...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viziteu, Elena, Grandmougin, Camille, Goldschmidt, Hartmut, Seckinger, Anja, Hose, Dirk, Klein, Bernard, Moreaux, Jerome
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782210/ https://www.ncbi.nlm.nih.gov/pubmed/26867162 http://dx.doi.org/10.1038/bjc.2016.20

Ejemplares similares

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
por: Viziteu, E, et al.
Publicado: (2017)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
por: Hassen, Wafa, et al.
Publicado: (2014)

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma
por: Kassambara, Alboukadel, et al.
Publicado: (2012)

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2013)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
por: Kassambara, Alboukadel, et al.
Publicado: (2014)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
por: Mahtouk, Karène, et al.
Publicado: (2010)

Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells
por: Staab, Adrian, et al.
Publicado: (2007)

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
por: Hose, Dirk, et al.
Publicado: (2019)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
por: Ovejero, Sara, et al.
Publicado: (2022)

The Glycome of Normal and Malignant Plasma Cells
por: Moehler, Thomas M., et al.
Publicado: (2013)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
por: Viziteu, Elena, et al.
Publicado: (2016)

Chetomin rescues pathogenic phenotype of LRRK2 mutation in drosophila
por: Chua, Ling Ling, et al.
Publicado: (2020)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression
por: Kessler, Jacqueline, et al.
Publicado: (2010)

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells
por: Meißner, Tobias, et al.
Publicado: (2015)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2015)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
por: Stroh, Jacob, et al.
Publicado: (2022)

SULFs in human neoplasia: implication as progression and prognosis factors
por: Bret, Caroline, et al.
Publicado: (2011)

Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma
por: Cowan, Graeme, et al.
Publicado: (2015)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis
por: Granzow, Martin, et al.
Publicado: (2017)

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
por: Schmitt, Michael, et al.
Publicado: (2016)

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
por: Rossi, J-F, et al.
Publicado: (2009)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

JunB is a key regulator of multiple myeloma bone marrow angiogenesis
por: Fan, Fengjuan, et al.
Publicado: (2021)

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
por: Tirier, Stephan M., et al.
Publicado: (2021)

Quantification of plasma cell dynamics using mathematical modelling
por: Mohr, Marcel, et al.
Publicado: (2018)

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
por: Merz, Maximilian, et al.
Publicado: (2019)

SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma
por: Moreaux, Jerome
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dqjjm8qr299l8k0fssvvhuk838